Predictive factors for mortality in elderly Japanese patients with severe microscopic polyangiitis: A retrospective single-center study

References

• Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42(3):421–30.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Uezono S, Hisanaga S, Fukudome K, Kobayashi S, Suzuki K, et al. Incidence of ANCA-associated primary renal vasculitis in the Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol. 2006;1(5):1016–22.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford). 2011;50(10):1916–20.
   PubMed Web of Science ®Google Scholar
• Watts RA, Scott DG, Jayne DR, Ito-Ihara T, Muso E, Fujimoto S, et al. Renal vasculitis in Japan and the UK-are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant. 2008;23(12):3928–31.
   PubMed Web of Science ®Google Scholar
• Sugiyama K, Sada KE, Kurosawa M, Wada J, Makino H. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. Clin Exp Nephrol. 2013;17(1):51–8.
   PubMed Web of Science ®Google Scholar
• Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, et al. Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74(1):177–84.
   PubMed Web of Science ®Google Scholar
• Watts RA, Scott DG. ANCA vasculitis: to lump or split? Why we should study MPA and GPA separately. Rheumatology (Oxford). 2012;51(12):2115–7.
   PubMed Web of Science ®Google Scholar
• de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670–80.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979;301(5):235–8.
   PubMed Web of Science ®Google Scholar
• Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71(6):955–60.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310–17.
   PubMed Web of Science ®Google Scholar
• Ntatsaki E, Carruthers D, Chakravarty K, D'Cruz D, Harper L, Jayne D, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306–9.
   PubMed Web of Science ®Google Scholar
• Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44.
   PubMed Web of Science ®Google Scholar
• Adler S, Villiger PM. B cell strategy to maintain remission in ANCA-associated vasculitides? J Rheumatol. 2012;39(1):4–5.
   PubMed Web of Science ®Google Scholar
• De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461–9.
   PubMed Web of Science ®Google Scholar
• Schonermarck U, Rau S, Fischereder M. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(21):2072. Author reply 2073-4.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.
   PubMed Web of Science ®Google Scholar
• Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.
   PubMed Web of Science ®Google Scholar
• Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13(6):633–50.
   PubMed Web of Science ®Google Scholar
• No author. Guidelines for the treatment of rapidly progressive glomerulonephritis, second version. Nihon Jinzo Gakkai Shi. 2011;53(4):509–55.
   PubMedGoogle Scholar
• Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17–28.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19–27.
   PubMed Web of Science ®Google Scholar
• Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56(2):87–96.
   PubMedGoogle Scholar
• Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2012;22(3):394–404.
   PubMed Web of Science ®Google Scholar
• Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671–8.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827–32.
   PubMed Web of Science ®Google Scholar
• Furuta S, Chaudhry AN, Hamano Y, Fujimoto S, Nagafuchi H, Makino H, et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol. 2014;41(2):325–33.
   PubMed Web of Science ®Google Scholar
• `Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67(7):1004–10.
   PubMed Web of Science ®Google Scholar
• Higgins RM, Goldsmith DJ, Connolly J, Scoble JE, Hendry BM, Ackrill P, et al. Vasculitis and rapidly progressive glomerulonephritis in the elderly. Postgrad Med J. 1996;72(843):41–4.
   PubMed Web of Science ®Google Scholar
• Hoganson DD, From AM, Michet CJ. ANCA vasculitis in the elderly. J Clin Rheumatol. 2008;14(2):78–81.
   PubMed Web of Science ®Google Scholar
• Tarzi RM, Pusey CD. Vasculitis: risks and rewards of treating elderly patients with vasculitis. Nat Rev Nephrol. 2011;7(5):253–5.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Quemeneur T, Ninet J, Diot E, Kyndt X, de Wazieres B, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67(4):1117–27.
   PubMed Web of Science ®Google Scholar
• Timlin H, Lee SM, Manno RL, Seo P, Geetha D. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Semin Arthritis Rheum. 2015;45(1):67–9.
   PubMed Web of Science ®Google Scholar